Category Archives: Latanoprost

Androgenetic Alopecia, Latanoprost, Latanoprost Acid, Psoriasis

BioResearch Pharma BRP-011: Latanoprost Acid for Hair Growth

6 Comments
Bioresearch Pharma BRP-011 Latanoprost Acid
Bioresearch Pharma BRP-011: Latanoprost Acid for Hair Growth.
Latanoprost Eyelash Hair Growth
Latanoprost Eyelash Hair Growth. Source: Nature, July 1998.

In just the past month, I covered two different companies working on a latanoprost based hair loss treatment (Canada-based Triple Hair and US-based Dermaliq). Both companies are almost certain to continue to Phase 3 clinical trials in the near future.

I also covered US-based Aneira Pharma and its latanoprost containing combination hair loss product in 2021. While the company has not updated its website for a few years, its patent application status page has been updated a few times in 2024.

Latanoprost is a prostaglandin F2α analogue eye medication that is meant to be used to treat glaucoma and ocular hypertension. It was approved for medical use in the US in 1996. An unusual side effect of latanoprost is increased and thicker eyelash hair growth. A rarer side effects is eyelash hair darkening (see image above from here).

BioResearch Pharma BRP-011: Latanoprost Acid for Hair Growth

Now comes news of BioResearch Pharma (Poland) working on a latanoprost acid based hair loss product called BRP-011. Thanks to “Ben” for posting a link to a very encouraging recent Polish magazine interview with CEO Lukasz Zybaczyński. This company was originally mentioned by “John Doe” in a comment earlier this year, and he also e-mailed me the above interview link.

According to the BRP-011 product page:

  • Latanoprost’s high skin penetration rate has raised concerns about potential systemic adverse side effects.
  • Consequently, latanoprost acid (an active metabolite of latanoprost) has emerged as an alternative option.
  • Latanoprost acid was initially dismissed as a potential topical treatment due to its low bioavailability.
  • However, BioResearch Pharma (BRP)’s chief scientific officer and co-founder Dr. Katarzyna Koziak has shown latanoprost acid to promote hair growth in a clinical setting involving indiviuals with androgenetic alopecia.

Note that BRP is only focusing on treating two conditions: androgenetic alopecia and psoriasis (via drug candidate BRP-007).

Commercialization in 2027

In the new CEO interview, the most interesting points relate to a very optimistic timeline forecast due to the nature of BRP’s products. Key quotes in bullet points (wording slightly modified by me):

  • BioResearch Pharma does not want to discover a new medicine and prove its safety, which usually takes years. The company intend to use an existing active substance in a new mechanism of action in a new route of administration. Regulatory agencies allow the registration of a medicine in a new therapeutic indication, using publications and data that are not the property of the applicant.
  • In the case of a new chemical molecule, the initial stages of the drug development process related to production and pre-clinical evaluation take around 5 to 7 years. In BRP’s repositioning process, they shorten this period to a year, relying on the past experiences of other pharmaceutical companies and patients. This method confirms safety standards.
  • In total, an up to 9 year process will be shortened to 2-3 years by BRP. i.e., much faster clinical trials.
  • In 2025, the company will begin the registration process.
  • The CEO anticipates commercialization after completing Phase I of clinical trials. This should happen by the end of 2026 for both projects (androgenetic alopecia and psoriasis). So commercialization in 2027.

The latter part of the interview relates to fundraising and a pending IPO.

Dermaliq Therapeutics, Latanoprost, PGF2a, Prostaglandin F2α

Dermaliq Therapeutics DLQ01 Prostaglandin F2α Analogue Topical

15 Comments

Update: Official announcement published on July 16. Better results than Minoxidil, and very optimistic statements regarding pursuing final clinical trials:

  • DLQ01 treatment increased total area hair count (TAHC) by 12.3% from baseline.
  • 83% of subjects responded with a positive increase in hair growth.
  • The comparator drug minoxidil increased TAHC by 9.8% from baseline.

Still no mention of Latanoprost. They just say that DLQ01 is a prostaglandin F2α analog, based on Dermaliq’s novel hyliQ® technology. The latter enables targeted rapid delivery of active ingredients into hair follicles.

July 15, 2024

Dermaliq Logo

Dermaliq Therapeutics DLQ01: Phase 2 Clinical Trials Successful

I first mentioned Dermaliq Therapeutics in a 2022 update to my 2020 post on increasing prostaglandin E2 (PGE2) and prostaglandin F2α (also called PGF2α or PGF2 alpha) for hair growth. The US-based privately-held company is working on a topical Prostaglandin F2α analogue hair growth product called DLQ01 (thought to contain latanoprost). It is based on Dermaliq’s novel and proprietary platform technology called hyliQ®.

The company claims that hyliQ “offers cutaneous drug delivery with unmatched bioavailability for a wide range of pharmaceutical actives”. In 2022, Dermaliq started Phase 1b/2a clinical trials for DLQ01 at Sinclair Dermatology in Melbourne, Australia. This clinic is run by the renowned dermatologist Dr. Rodney Sinclair, who I have written about numerous times in the past.

Dermaliq Therapeutics DLQ01
Dermaliq Therapeutics DLQ01 topical formulation of a prostaglandin F2α analog in hyliQ®.

Earlier today, reader “John Doe” found an update on Dermaliq’s pipeline page which suggests that Phase 2 trials are finished and the results were very good. See the above screenshot. It says the following:

“DLQ01 Phase 2 data has impressively demonstrated its superior efficacy. The number of hairs in the target area increased effectively with high statistical significance compared to the vehicle. More than 80% of subjects responded with a positive change in hair growth. We are continuing clinical development based on a clear regulatory pathway to approval.”

To me, this signals that Phase 3 clinical trials are now a certainty. The company’s news page has not been updated since December 2022, but I suspect that this will change soon.

Note that DLQ01 is said to grow hair in both men and women suffering from androgenetic alopecia (aka male and female pattern baldness). According to Dr. Betsy Hughes-Formella (Chief Scientific Officer at Dermaliq):

“Dermaliq’s hyliQ® technology has the potential to transform follicular and dermal delivery of a broad range of active ingredients. DLQ01 is just the start of a promising pipeline targeting follicular delivery.”

Prostaglandin F2α Analogue Latanoprost

Prostaglandin F2α analogue Latanoprost has already proven to grow eyelash hair longer and thicker. Latanoprost (brand name Xalatan) is a medication that is meant to be used to treat glaucoma  and hypertension in the eyes. It was approved for medical use in the US in 1996. The eyelash hair growth (and darkening) was a notable side effect.

Several companies are developing combination hair growth products based on Latanoprost. The most promising of these is Triple Hair (Canada), which is on the verge of commencing Phase 3 clinical trials. Another company called Aneira Pharma (US) does not seem to have updated it website for several years. However, the company’s hair growth related patent applications are still being updated as of 2024 (h/t “John Doe”).